Mostly Markets
Subscribe
Stocks/Health Care/Life Sciences Tools & Services

Bio-TechneTECH

Life Sciences Tools & Services · Minneapolis, Minnesota · In the S&P 500
Solid businessPricier than peers
$72.66−0.07%After hours: $72.66 (0.00%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 17.2% over 1 year
Bio-Techne over 1 yearDaily close, $, to 30 Oct 2026
$50$60$70Nov2026MarMayJulSep$72.66$60NovMarJul$72.66
Source: Nasdaq daily closes
Market value$11.41B
Price to earnings62.8x
Forward P/E35.4x
Dividend yield0.44%
Year to date+23.6%
One year+17.2%
Next earningsWed 4 Nov
SectorHealth Care
52-week range (closes)
$43.30$72.71

Quality and valuation

How Bio-Techne compares with other health care stocks. A description, not a recommendation.

Bio-Techne and 7 life sciences tools & services peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: pricier than most

An average business among health care companies, priced above most of them.

Bio-Techne trades at 35.4 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: −0.4% vs +7.8%
  • Keeps more of each sale (gross margin): 65.8% vs 65.3%
  • More profitable (operating margin): 20.7% vs 13.3%
  • Turns more of its sales into cash: 21.7% vs 15.9%
TECH trades at 35.4x forward earnings, above the sector medianForward p/e, Life Sciences Tools & Services peers
IQV19.8xDHR26.5xTMO26.6xA26.6xWAT29.8xMTD34.1xTECH35.4xILMN41.6xSector median 19.1xIQV19.8xDHR26.5xTMO26.6xA26.6xWAT29.8xMTD34.1xTECH35.4xILMN41.6xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 63.2x earnings, TECH is cheaper than its average since Aug 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
50x100xAverage 86.7x2025202663.2x50x100xAverage 86.7x2025202663.2x
Source: Nasdaq prices; SEC filings

Financials

From Bio-Techne's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 1.3% from a year earlierQuarterly revenue, $m, latest Q4 ’26
$0m$100m$200m$300mQ1 ’25Q3 ’25Q1 ’26$321mQ4 ’26$0m$200mQ1 ’25Q3 ’25Q1 ’26$321mQ4 ’26
Source: SEC filings
Growth sped up to +1.3% last quarterRevenue growth, year on year, %
0%5%Q1 ’25Q3 ’25Q1 ’261.3%Q4 ’260%5%Q1 ’25Q3 ’25Q1 ’261.3%Q4 ’26
Source: SEC filings
Operating margin was 23.1% last quarterOperating income as a share of revenue, %
0%10%20%Q1 ’25Q3 ’25Q1 ’2623.1%Q4 ’260%20%Q1 ’25Q3 ’25Q1 ’2623.1%Q4 ’26
Source: SEC filings
Free cash flow was $263 million over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$25m$50m$75mQ1 ’25Q3 ’25Q1 ’26$87mQ4 ’26$0m$50mQ1 ’25Q3 ’25Q1 ’26$87mQ4 ’26
Source: SEC filings
Last 12 monthsTECHSector median
Revenue growth−0.4%+7.8%
Gross margin65.8%65.3%
Operating margin20.7%13.3%
Free cash flow margin21.7%15.9%
Price to earnings62.8x30.2x

Stories on Bio-Techne

We haven't written about Bio-Techne yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Life Sciences Tools & Services, by market value.

CompanyPriceTodayYTDValue
TMOThermo Fisher Scientific$697.00−1.72%+20.3%$258B
DHRDanaher$232.23−2.00%+1.4%$163B
AAgilent Technologies$174.87−3.47%+28.5%$49.30B
WATWaters$462.72−3.61%+21.8%$45.46B
IQVIQVIA$267.33−2.81%+18.6%$44.06B
ILMNIllumina$235.99−18.64%+79.9%$35.63B
MTDMettler Toledo$1,674.81−2.55%+20.1%$33.56B
CRLCharles River Laboratories$359.41−4.44%+80.2%$17.16B